Positron (POSC) and Its Competitors Critical Comparison

Positron (OTCMKTS:POSC) is one of 70 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Positron to similar businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Valuation & Earnings

This table compares Positron and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-12.00
Positron Competitors	$1.09 billion	$91.03 million	-9.93

Positron’s rivals have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Positron and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	266	796	1962	58	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,073.04%. Given Positron’s rivals higher possible upside, analysts plainly believe Positron has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

45.8% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 13.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Positron and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-344.53%	-46.15%	-24.71%

Volatility and Risk

Positron has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Positron’s rivals have a beta of 18.19, suggesting that their average share price is 1,719% more volatile than the S&P 500.

Summary

Positron rivals beat Positron on 7 of the 10 factors compared.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.